Coverage List (As of November 29, 2012)

Ticker Company Rating Price Price Target 52 Week High Low EPS FY12E FY13E FY12E P/E FY13E Book Value* Market Cap (mm)* FY End

Raghuram Selvaraju, Head of Healthcare Research - (646) 502-2464, rselvaraju@aegiscap.com

Biopharmaceuticals
ACOR AMPE AMRN AUXL BLRX BSTC CDXC GALT IGXT MDVN SCLN Acorda Therapeutics, Inc. Ampio Pharmaceuticals, Inc. Amarin Corporation Auxilium Pharmaceuticals, Inc. BioLineRx, Ltd. BioSpecifics Technologies Corp. ChromaDex Corp. Galectin Therapeutics, Inc. IntelGenx Technologies Corp. Medivation, Inc. SciClone Pharmaceuticals, Inc. Buy Buy Buy Buy Buy Buy Buy Buy Buy Buy Buy $24.72 $3.99 $14.00 $18.40 $2.71 $19.50 $0.95 $1.89 $0.61 $45.95 $4.03 $34.00 $11.00 $25.00 $35.00 $11.00 $50.00 $3.00 $7.00 $3.00 $100.00 $10.00 $27.74 $8.50 $15.96 $29.37 $6.87 $21.99 $1.25 $6.78 $0.74 $58.83 $7.58 $20.86 $2.54 $5.99 $14.28 $2.20 $12.68 $0.44 $1.61 $0.40 $20.56 $3.68 $0.66 ($0.31) ($1.40) $1.78 ($1.04) $0.91 ($0.18) ($0.71) ($0.04) ($0.17) $0.22 EPS FY12E FY13E FY12E $0.69 ($0.37) $0.41 $0.11 ($0.81) $1.88 ($0.10) ($0.65) $0.01 $0.63 $0.73 37.5x --10.3x -21.4x ----18.3x P/E FY13E 35.8x -34.1x --10.4x --61.0x 72.9x 5.5x $6.22 $0.43 ($0.47) $2.20 $1.39 $2.55 $0.06 $0.40 $0.06 $1.28 $2.89 Book Value* $991 $148 $1,910 $902 $48 $125 $88 $30 $30 $3,410 $228 Market Cap (mm)* December December December December December December December December December December December

Ticker

Company

Rating

Price

Price Target

52 Week High Low

FY End

Raghuram Selvaraju, Head of Healthcare Research - (646) 502-2464, rselvaraju@aegiscap.com

Biotechnology
CUR GALE IRWD LPTN NVIV PBTH PLX SGYP SSRX TSRX Neuralstem, Inc. Galena Biopharma, Inc. Ironwood Pharmaceuticals, Inc. Lpath, Inc. InVivo Therapeutics Holdings Corp. PROLOR Biotech, Inc. Protalix BioTherapeutics, Inc. Synergy Pharmaceuticals, Inc. 3SBio, Inc. Trius Therapeutics, Inc. Buy Buy Buy Buy Buy Buy Hold Buy Buy Buy $1.10 $1.58 $12.25 $6.54 $1.56 $5.10 $4.87 $3.75 $13.33 $4.74 $3.00 $6.00 $18.00 $40.00 $5.00 $12.00 $5.50 $25.00 $25.00 $15.00 $1.96 $3.54 $15.92 $9.80 $3.23 $6.69 $7.70 $7.08 $15.33 $8.00 $0.42 $0.36 $10.65 $4.55 $1.25 $3.11 $4.29 $2.00 $9.26 $4.66 ($0.17) ($0.60) ($0.59) ($0.38) $0.14 ($0.28) ($0.17) ($0.65) $0.71 ($1.49) EPS FY12E FY13E FY12E ($0.18) ($0.37) ($1.15) ($0.21) ($0.29) ($0.32) ($0.17) ($0.69) $0.79 ($1.19) ----11.1x ---18.8x -P/E FY13E --------16.9x -$0.08 $0.21 $1.70 $0.64 ($0.07) $0.67 ($0.07) $0.63 $9.51 $1.58 Book Value* $60 $106 $1,313 $69 $100 $323 $448 $247 $295 $187 Market Cap (mm)* December December December December December December December December December December

Ticker

Company

Rating

Price

Price Target

52 Week High Low

FY End

Raghuram Selvaraju, Head of Healthcare Research - (646) 502-2464, rselvaraju@aegiscap.com

Molecular Diagnostics
ROSG Rosetta Genomics Buy $6.51 $16.00 $23.43 $1.40 ($1.88) ($0.65) --$54 December

Coverage List (As of November 29, 2012)

IMPORTANT DISCLOSURES

*This data reflects what was published in the last research document for each company. Research analyst compensation is dependent, in part, upon investment banking revenues received by Aegis Capital Corp. Aegis Capital Corp. intends to seek or expects to receive compensation for investment banking services from the subject company within the next three months. Meaning of Ratings A) A Buy rating is assigned when we do not believe the stock price adequately reflects a company's prospects over 12-18 months. B) A Hold rating is assigned when we believe the stock price adequately reflects a company's prospects over 12-18 months. C) A Sell rating is assigned when we believe the stock price more than adequately reflects a company's prospects over 12-18 months. The information contained herein is based upon sources believed to be reliable but is not guaranteed by us and is not considered to be all inclusive. It is not to be construed as an offer or the solicitation of an offer to sell or buy the securities mentioned herein. Aegis Capital Corp., its affiliates, shareholders, officers, staff, and/or members of their families, may have a position in the securities mentioned herein, and, before or after your receipt of this report, may make or recommend purchases and/or sales for their own accounts or for the accounts of other customers of the Firm from time to time in the open market or otherwise. Opinions expressed are our present opinions only and are subject to change without notice. Aegis Capital is under no obligation to provide updates to the opinions or information provided herein. Additional information is available upon request. Copyright 2012 by Aegis Capital Aegis Capital Corp. (212) 813-1010 810 Seventh Avenue, 18th Floor New York, New York 10019

Page 2 of 2